This week on PharmTech, Merck diversified its pipeline, USP emphasizes supply chain security, AI systems are examined, and speakers preview their presentations at CPHI Milan and AAPS PharmSci 360.
|Articles|August 10, 2006
FDA Nanotech Task Force Schedules October Meeting
Author(s)Pharmaceutical Technology Editors
On Oct. 10, the US Food and Drug Administration (Rockville, MD) will hold a public meeting on products containing nanotechnology materials.
Advertisement
On Oct. 10, the US Food and Drug Administration (Rockville, MD,
The Agency's new Nanotechnology Task Force stated "we are interested in learning about the kinds of new nanotechnology material products under development in the areas of foods (including dietary supplements), food and color additives, animal feeds, cosmetics, drugs and biologics, and medical devices," according to the meeting announcement. The announcement, "Food and Drug Administration-Regulated Products Containing Nanotechnology Materials; Public Meeting" (Docket No. 2006N-0107) is scheduled for publication in the Aug. 11 Federal Register (with a preview draft posted online at
The meeting will be held at the Natcher Auditorium at the National Institutes of Health, 9000 Rockville Pike, Building 45, Bethesda, MD. Those who would like to attend should register at the Nanotechnology Task Force's Web page,
www.fda.gov/nanotechnology/
, which will also post additional background material and the meeting agenda.
Advertisement
Related to this article
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.
The FDA opened an expedited IND pilot, tightened scrutiny of foreign trial data, and finalized a rule recognizing non-animal testing methods. In Europe, the EMA advanced pharmaceutical legislation reform, restricted 2 legacy products, and opened an injectable-iron safety review.
Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Ronald Piervincenzi, USP, explains why drug supply resilience needs a system approach, from procurement benchmarks to regulatory capacity building.
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Advertisement
Advertisement